Bramante Stefano, Di Salvo Gabriele, Maina Giuseppe, Rosso Gianluca
Rita Levi Montalcini Department of Neurosciences, University of Turin, Turin, Italy.
Psychiatry Department, San Luigi Gonzaga University Hospital, Orbassano, Italy.
Neuropsychiatr Dis Treat. 2023 Mar 7;19:519-530. doi: 10.2147/NDT.S374696. eCollection 2023.
International guidelines suggest long-term antipsychotic therapies for treating schizophrenia; however, medication compliance remains a critical issue in schizophrenia. Paliperidone palmitate (PP) is a second-generation antipsychotic long-acting injectable (SGA-LAI) approved for the treatment of schizophrenia. To date, the majority of studies on PP compliance patterns did not use specific instruments to assess medications' adherence, have been performed in not naturalistic samples and present partially overlapping populations. We conducted a systematic review in which we aimed to review the current knowledge on PP-LAI adherence levels and to describe healthcare resource utilisation and costs related to PP-LAI treatment. The evaluation has been conducted by searching in different databases (PubMed, Ovid, Scopus, and Cochrane Library) from inception to September 2022. Our findings suggest that paliperidone palmitate should be considered a good treatment strategy for patients affected by schizophrenia: PP showed both a good efficacy and tolerability and better adherence patterns and more favourable healthcare resource utilisation and costs, compared to OA.
国际指南建议采用长期抗精神病药物治疗精神分裂症；然而，药物依从性仍是精神分裂症治疗中的一个关键问题。棕榈酸帕利哌酮（PP）是一种第二代长效注射用抗精神病药物（SGA-LAI），已被批准用于治疗精神分裂症。迄今为止，大多数关于PP依从性模式的研究未使用特定工具来评估药物依从性，研究对象并非来自自然样本，且研究人群部分重叠。我们进行了一项系统综述，旨在回顾目前关于PP-LAI依从性水平的知识，并描述与PP-LAI治疗相关的医疗资源利用情况和成本。通过检索不同数据库（PubMed、Ovid、Scopus和Cochrane图书馆）中从数据库建立至2022年9月的文献进行评估。我们的研究结果表明，棕榈酸帕利哌酮应被视为治疗精神分裂症患者的一种良好治疗策略：与口服抗精神病药物（OA）相比，PP显示出良好的疗效和耐受性、更好的依从性模式以及更有利的医疗资源利用情况和成本。
